Core Viewpoint - A class action securities lawsuit has been filed against Flywire Corporation, alleging securities fraud that affected investors between February 28, 2024, and February 25, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Flywire's revenue growth was overstated, and the negative impact of permit and visa-related restrictions on its business was understated [2]. - Defendants' public statements regarding Flywire's business performance were materially false and misleading throughout the relevant period [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 23, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Law Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - A class action securities lawsuit has been filed against KinderCare Learning Companies, Inc. due to alleged securities fraud affecting investors who purchased shares during the October 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to KinderCare Learning Companies, Inc. [2] - The complaint alleges that KinderCare concealed incidents of child abuse, neglect, and harm at its facilities, failed to provide high-quality care, and did not meet minimum standards in the child care industry [3]. - As a result of these issues, KinderCare is said to be exposed to undisclosed risks including lawsuits, regulatory actions, negative publicity, reputational damage, and business loss [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until October 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, alleging securities fraud that affected investors between December 27, 2023, and May 6, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Cytokinetics made materially false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten [2]. - Defendants indicated that they expected FDA approval for aficamten in the second half of 2025, based on a PDUFA date of September 26, 2025, while failing to disclose risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [2]. - On May 6, 2025, it was revealed during an earnings call that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2]. Group 2: Investor Information - Investors who suffered losses in Cytokinetics during the relevant period have until November 17, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in V.F. Corporation ("V.F. Corporation" or the "Company") (NYSE: VFC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of V.F. Corporation investors who were adversely affected by alleged securities fraud between October 30, 2023 and May 20, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/v-f-corporati ...

Core Viewpoint - A class action securities lawsuit has been filed against Sable Offshore Corp. due to alleged securities fraud affecting investors who purchased shares between May 19, 2025, and June 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged false statements made by the company regarding its oil production activities off the coast of California [3]. - The complaint claims that Sable Offshore Corp. misrepresented its business operations and prospects, leading to materially false and misleading statements [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 26, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc. investors who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/p ...

Core Viewpoint - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. due to alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. - It is alleged that the regulatory prospects of the oxylanthanum carbonate new drug application were also overstated [2]. - Defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 14, 2025, to request appointment as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4].

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Lockheed Martin Corporation ("Lockheed Martin Corporation" or the "Company") (NYSE: LMT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lockheed Martin Corporation investors who were adversely affected by alleged securities fraud between January 23, 2024 and July 21, 2025. Follow the link below to get more information and be contacted by a member of our team: htt ...

Core Viewpoint - A class action securities lawsuit has been filed against Dow Inc. alleging securities fraud that negatively impacted investors between January 30, 2025, and July 23, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Dow Inc. overstated its ability to manage macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [2]. - It is alleged that the negative impacts of competitive pressures, declining global sales, and product oversupply on Dow's business were understated [2]. - The defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 28, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S, alleging securities fraud that negatively impacted investors between May 7, 2025, and July 28, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Novo Nordisk made misleading statements regarding its growth potential, particularly underestimating the impact of the personalization exception to the compounded GLP-1 exclusion and overstating the likelihood of patients switching to its branded alternatives [2]. - On July 29, 2025, Novo announced a reduction in its sales and profit outlook, attributing this to lower growth expectations for Wegovy and Ozempic due to competition and the persistent use of compounded GLP-1s [2]. - Following the announcement, Novo's stock price plummeted from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, marking a decline of approximately 21.83% in one day [2]. Group 2: Legal Proceedings and Participation - Investors who suffered losses during the specified timeframe have until September 30, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].